Redx, the drug development company, is pleased to announce that it will present the pre-clinical profile of its reversible Bruton’s tyrosine kinase (“BTK”) inhibitor at the American Society of Hematology (ASH) Annual Meeting on 5 December 2016 in San Diego, California. The compound, named RXC005 (also known as REDX08608), is a novel, potent and selective, reversible BTK inhibitor that is equipotent against wild-type and mutant C481S BTK. C481 mutant BTK protein is currently estimated to be responsible for around 60% of the observed ibrutinib resistance in patients with chronic lymphocytic leukaemia.
The Company is progressing studies to prepare the RXC005 program for first-in-human clinical trials. The aim is to commence these trials late 2017.
The Abstract for the presentation is available on the ASH Conference website: https://ash.confex.com/ash/2016/webprogram/Paper92759.html
Dr Neil Murray, CEO of Redx, said:
“We’re delighted to present the compelling pre-clinical profile of our reversible BTK inhibitor RXC005 at the prestigious American Society of Hematology Annual Meeting in December.
“RXC005 has the potential to become a potent therapy for chronic lymphocytic leukaemia patients by tackling the growing resistance to ibrutinib treatment. We aim to initiate first-in-human clinical studies for RXC005 late 2017.”
For further information, please contact:
Redx Pharma Plc
Neil Murray, Chief Executive T: +44 151 706 4747
Karl Hård, Head of Investor Relations &
Corporate Communications T: +44 7491 651 406
Cantor Fitzgerald Europe (Nomad & Broker)
T: +44 20 7894 7000
Phil Davies/ Michael Reynolds
About Redx Pharma Plc
Company website: Redxpharma.com
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary drug programs. Seven proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, gonorrhoea, bone tumours, skin, brain, breast, pancreatic and blood cancers.
